Palatin Technologies Inc (PTN)
1.79
+0.03
(+1.70%)
USD |
NYAM |
Jul 05, 15:52
Palatin Technologies SG&A Expense (Annual): 15.29M for June 30, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
June 30, 2023 | 15.29M |
June 30, 2022 | 16.51M |
June 30, 2021 | 17.34M |
June 30, 2020 | 9.765M |
June 30, 2019 | 9.699M |
June 30, 2018 | 8.642M |
June 30, 2017 | 9.610M |
June 30, 2016 | 6.179M |
June 30, 2015 | 5.678M |
June 30, 2014 | 4.961M |
June 30, 2013 | 5.067M |
June 30, 2012 | 5.046M |
June 30, 2011 | 4.752M |
June 30, 2010 | 4.901M |
Date | Value |
---|---|
June 30, 2009 | 5.297M |
June 30, 2008 | 6.928M |
June 30, 2007 | 7.293M |
June 30, 2006 | 6.844M |
June 30, 2005 | 8.324M |
June 30, 2004 | 5.740M |
June 30, 2003 | 4.867M |
June 30, 2002 | 5.004M |
June 30, 2001 | 3.025M |
June 30, 2000 | 4.567M |
June 30, 1999 | 4.00M |
June 30, 1998 | 3.00M |
June 30, 1997 | 2.50M |
June 30, 1996 | 1.250M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
9.765M
Minimum
2020
17.34M
Maximum
2021
14.73M
Average
15.90M
Median
SG&A Expense (Annual) Benchmarks
Perspective Therapeutics Inc | 21.06M |
Outset Medical Inc | 141.46M |
Ligand Pharmaceuticals Inc | 52.79M |
Lumos Pharma Inc | 16.57M |
Galectin Therapeutics Inc | 5.942M |